PMID- 34565301
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20220216
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Dec
TI  - Glycolysis related gene expression signature in predicting prognosis of laryngeal 
      squamous cell carcinoma.
PG  - 8738-8752
LID - 10.1080/21655979.2021.1980177 [doi]
AB  - Researches have suggested that aerobic glycolysis can reflect the development and 
      progression of most carcinomas. We aimed to investigate whether 
      glycolysis-related genes (GRGs) are associated with overall survival in laryngeal 
      squamous cell carcinoma (LSCC). Here, we identified differentially expressed GRGs 
      in TCGA dataset and microarray sample of GSE27020 from GEO database. A set of two 
      glycolytic gene signatures, including DDIT4 and PLOD2 was screened through Cox 
      and Lasso regression. The risk score was calculated using the gene expression of 
      the two GRGs. The high-risk group presented a poor prognosis through Kaplan-Meier 
      method. The ROC curve indicated good prediction performance in survival based on 
      the validation of four cohorts. Univariate and multivariate Cox regression 
      analyses suggested that two-gene signature could be an independent risk factor in 
      LSCC. A total of 17 LSCC patients were enrolled to clarify the genetic expression 
      through using reverse transcription-polymerase chain reaction (RT-PCR). A 
      visualized nomogram was then constructed to predict 1-, 3-, and 5-year overall 
      survival. Taken together, two novel glycolytic gene signatures were discovered 
      and validated, providing a potential therapeutic and overall survival 
      (OS)-prediction biomarker for LSCC.
FAU - Lau, Hui-Ching
AU  - Lau HC
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, China.
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, PR China.
FAU - Shen, Yujie
AU  - Shen Y
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, China.
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, PR China.
FAU - Huang, Qiang
AU  - Huang Q
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, China.
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, PR China.
FAU - Huang, Hui-Ying
AU  - Huang HY
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, China.
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, PR China.
FAU - Zhou, Liang
AU  - Zhou L
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, China.
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Carcinoma, Squamous Cell/genetics/metabolism/pathology
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Glycolysis
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/metabolism/*pathology
MH  - *Nomograms
MH  - Prognosis
MH  - ROC Curve
MH  - Survival Rate
MH  - *Transcriptome
PMC - PMC8806568
OTO - NOTNLM
OT  - GEO
OT  - Laryngeal squamous cell carcinoma
OT  - TCGA
OT  - gene signature
OT  - prognosis
COIS- All authors stated no conflict of interest in this study.
EDAT- 2021/09/28 06:00
MHDA- 2022/02/17 06:00
PMCR- 2021/10/29
CRDT- 2021/09/27 05:28
PHST- 2021/09/28 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
PHST- 2021/09/27 05:28 [entrez]
PHST- 2021/10/29 00:00 [pmc-release]
AID - 1980177 [pii]
AID - 10.1080/21655979.2021.1980177 [doi]
PST - ppublish
SO  - Bioengineered. 2021 Dec;12(1):8738-8752. doi: 10.1080/21655979.2021.1980177.